VYRIXFLU Trademark
Trademark Overview
On Wednesday, December 11, 2024, a trademark application was filed for VYRIXFLU with the United States Patent and Trademark Office. The USPTO has given the VYRIXFLU trademark a serial number of 98896125. The federal status of this trademark filing is APPROVED FOR PUBLICATION as of Thursday, September 18, 2025. This trademark is owned by GlaxoSmithKline Biologicals SA. The VYRIXFLU trademark is filed in the Pharmaceutical Products category with the following description:
Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders
General Information
| Serial Number | 98896125 |
| Word Mark | VYRIXFLU |
| Filing Date | Wednesday, December 11, 2024 |
| Status | 680 - APPROVED FOR PUBLICATION |
| Status Date | Thursday, September 18, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
Trademark Statements
| Goods and Services | Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, December 11, 2024 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | GlaxoSmithKline Biologicals SA |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 33 - NOT AVAILABLE |
| Address | Rixensart B-1330
BE |
Trademark Events
| Event Date | Event Description |
| Wednesday, December 11, 2024 | NEW APPLICATION ENTERED |
| Monday, June 2, 2025 | EXAMINERS AMENDMENT -WRITTEN |
| Monday, June 2, 2025 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Monday, June 2, 2025 | EXAMINER'S AMENDMENT ENTERED |
| Wednesday, December 11, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Wednesday, May 28, 2025 | ASSIGNED TO EXAMINER |
| Monday, June 2, 2025 | LETTER OF SUSPENSION E-MAILED |
| Monday, June 2, 2025 | SUSPENSION LETTER WRITTEN |
| Monday, June 2, 2025 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Tuesday, September 16, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, September 16, 2025 | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED |
| Tuesday, September 16, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, September 18, 2025 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Monday, June 2, 2025 | EXAMINERS AMENDMENT E-MAILED |
